P1.21-09 Radiomic Signature of Identifies Outcome and Prognosis to Immune Checkpoint Inhibitors (ICI) in PD-L1 Low Non-small Cell Lung Cancer (NSCLC)

Immune checkpoint inhibitors (ICI) are the backbone of treating locally advanced and metastatic non-small cell lung cancer (NSCLC). While they usually work on the PD-1/PD-L1 axis, PD-L1 itself is not an ideal biomarker for determining response to ICI, with recent phase three clinical trials showing benefit of combination ICI on a portion of PD-L1 negative NSCLC patients. There is thus a need for development of more effective biomarkers of ICI response that can effectively stratify this population.